Cellectar Biosciences, Inc. (CLRB) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K, dated May 4, 2026, details a capital raise and recent clinical trial data for Cellectar Biosciences, Inc., a biopharmaceutical company developing iopofosine I 131 for the treatment of Waldenström macroglobulinemia (WM). The offering closed on May 6, 2026.
Key Financial Metrics and Capital Structure
- Gross Proceeds: Approximately $35 million from the Registered Direct Offering and Concurrent Private Placement, excluding future warrant exercises.
- Securities Issued:
- 1,618,053 Registered Shares of Common Stock.
- 2,116,887 Unregistered Shares of Common Stock.
- Pre-Funded Warrants to purchase 9,471,086 shares.
- 13,206,026 Milestone Warrants (Tranche A, B, and C) with an exercise price of $2.65.
- Management Participation: Executive management purchased shares and warrants at $2.88 per share.
- Transaction Costs: Placement agent fees include 8.0% cash fee on gross proceeds, 6.0% of shares/warrants as warrants, and 4.0% cash fee on cash exercises of Milestone Warrants. Expense reimbursement capped at $110,000.
- Post-Offering Share Count: 7,975,069 shares of Common Stock outstanding (excluding warrant shares).
- Use of Proceeds: Working capital, general corporate purposes, and initiating a Phase 3 trial for iopofosine I 131.
Material Changes and Corporate Actions
- Board Expansion: Nantahala Capital Management, LLC secured the right to appoint one independent director to the Board of Directors, with nomination due by June 5, 2026.
- Registration Rights: The Company agreed to file a registration statement for the resale of unregistered shares and warrant shares by May 19, 2026, with effectiveness required within 60 days.
- Warrant Call Provisions: Milestone Warrants are callable by the Company if the stock price exceeds 130% of the exercise price ($2.65) for 20 consecutive trading days with sufficient volume, contingent on specific clinical milestones (Trial initiation, NDA acceptance, or NDA approval).
Clinical Data, Outlook, and Risks
The filing references positive 12-month follow-up data from the Phase 2b CLOVER WaM trial (reported May 5, 2025) supporting the planned Phase 3 trial:
- Overall Response Rate (ORR): 83.6%
- Major Response Rate (MRR): 61.8% (Primary endpoint achieved)
- Median Duration of Response: 17.8 months
- Median Progression-Free Survival: 13.5 months
- Safety Profile: Adverse events were transient; no significant bleeding events; low infection rates (<10%). Cytopenias were the most common adverse events.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Success of the Phase 3 trial and subsequent FDA approval are not guaranteed. The Company's liquidity is dependent on the successful execution of this offering and future capital raises.
Investor Verification Checklist
- Verify the exact closing date and final gross proceeds received (filing states "expected" $35 million).
- Confirm the dilution impact of the Pre-Funded Warrants and Milestone Warrants upon exercise.
- Review the specific terms of the Board Designation Side Letter regarding the independence and qualifications of the Nantahala appointee.
- Monitor the timeline for the filing and effectiveness of the Registration Statement for the unregistered shares (deadline: May 19, 2026).
- Assess the Company's cash runway post-offering relative to the costs of initiating the Phase 3 trial.